Trial: 202008066

An Open-label, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI9253, a Recombinant Newcastle Disease Virus Encoding Interleukin-12, in Combination with Durvalumab in Participants with Select Advanced/Metastatic Solid Tumors



Principal Investigator

Johanns, Tanner

Disease Site

Colon; Kidney; Melanoma, Skin; Rectum

Learn more about this study at: